8-K/A: Q/C Technologies Amends 8-K for RSU Grant Disclosure

Q/C Technologies, Inc. filed an amended 8-K to disclose previously omitted Restricted Stock Unit grants totaling 225,000 RSUs to its directors and officers.

Summary

• Q/C Technologies, Inc. filed an Amendment No. 1 on Form 8-K/A to its Current Report on Form 8-K filed on October 3, 2025.
• The amendment was solely to include information regarding a grant of Restricted Stock Units (RSUs) to a director that was inadvertently omitted from the original report.
• On October 3, 2025, the Board of Directors approved grants of an aggregate of 225,000 RSUs to Joshua Silverman (Executive Chairman), Christopher Schriber, Bill White, Stephen Friscia, Mitchell Glass (Chief Medical Officer and director), Gary Rauch (Vice President of Finance), and Bruce Bernstein (director).
• Initial Grants totaling 17,287 RSUs were issued and fully vested on October 3, 2025, including 8,644 RSUs to Mr. Silverman, 2,161 RSUs each to Mr. Schreiber, Mr. White, and Mr. Friscia, and 1,080 RSUs each to Mr. Glass and Mr. Rauch.
• Additional Grants totaling 207,713 RSUs will be issued and fully vest upon receipt of stockholder approval to increase the shares reserved under the Q/C Technologies, Inc. 2021 Equity Incentive Plan. These include 91,356 RSUs to Mr. Silverman, 22,839 RSUs each to Mr. Schreiber, Mr. White, and Mr. Friscia, 11,420 RSUs each to Mr. Glass and Mr. Rauch, and 25,000 RSUs to Mr. Bernstein.
• All RSUs were or will be issued pursuant to the Company's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The filing is largely neutral, detailing standard compensation practices and a procedural correction. The RSU grants are a positive for management incentives but introduce potential dilution for shareholders, balancing the sentiment towards slightly positive due to transparency and incentive alignment.

Positives

• The RSU grants serve as an incentive and retention tool for key directors and officers, aligning their interests with long-term shareholder value.
• The company is transparent in correcting an omission, demonstrating commitment to accurate disclosure.

Negatives

• The issuance of 225,000 RSUs, particularly the 207,713 Additional Grants, will result in dilution for existing shareholders if stockholder approval is obtained and the shares are issued.
• The inadvertent omission of this information from the original report suggests a minor internal control oversight in reporting.

Risks

• The Additional Grants of 207,713 RSUs are contingent on stockholder approval to increase the shares reserved under the 2021 Equity Incentive Plan; if approval is not obtained, these grants will not be issued.

Future Outlook

The issuance and vesting of 207,713 Additional RSUs are contingent upon future stockholder approval to increase the shares reserved under the Company's 2021 Equity Incentive Plan.

Industry Context

This filing pertains to standard executive and director compensation practices through equity grants, a common method used across industries to align management and board interests with shareholder value. The need for stockholder approval for increasing shares under an equity plan is also a routine corporate governance matter.

Comparison to Industry Standards

• The practice of granting Restricted Stock Units (RSUs) to executive management and directors is a common compensation strategy across publicly traded companies, including those in the technology sector like Q/C Technologies, Inc.
• The specific number of RSUs (225,000 aggregate) would need to be benchmarked against companies of similar market capitalization, revenue, and industry to assess if it is within typical ranges for executive and director compensation. Without this comparative data, a definitive assessment against global benchmarks is not possible from the filing alone.
• The requirement for stockholder approval to increase the share pool for an equity incentive plan is a standard corporate governance practice, ensuring shareholder oversight on potential dilution.

Corporate Governance

Related Party Transactions

• The grant of 225,000 Restricted Stock Units to the Executive Chairman, Chief Medical Officer, Vice President of Finance, and other directors constitutes compensation to related parties.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of 225,000 RSUs, particularly the 207,713 Additional Grants contingent on stockholder approval. However, equity grants are intended to align management interests with shareholder value.
• Management and Directors: The RSU grants provide significant equity incentives, enhancing retention and motivation.

Next Steps

• The Company will seek stockholder approval for an increase in the shares reserved and available under the Q/C Technologies, Inc. 2021 Equity Incentive Plan.
• Upon obtaining stockholder approval, the Additional Grants of 207,713 RSUs will be issued and fully vest.

Key Dates

Recommendation

This filing is an amendment to correct an omission regarding RSU grants, which is a procedural matter and standard compensation practice. While the grants introduce potential dilution, they also serve as an incentive for key personnel. The information is not significant enough to warrant a strong buy or sell recommendation, suggesting a "hold" position as the core business fundamentals are not addressed.

Keywords

Q/C Technologies, QCLS, SEC Filing, 8-K/A, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Corporate Governance, Stockholder Approval, Dilution